VANCOUVER, BC, April 5, 2021 /CNW/ - Rakovina Therapeutics
Inc. (the "Company") (TSXV: RKV) is pleased to
announce the appointment of Julie M.
Cherrington, PhD to the Company's Board of Directors.
"We are delighted to welcome Dr. Cherrington to the Rakovina
Therapeutics team," said Mr. Jeffrey
Bacha, Rakovina Therapeutics' executive chairman. "The
addition of an executive leader with Dr. Cherrington's experience
and talent to our Board of Directors will greatly benefit Rakovina
Therapeutics as we advance our pipeline of novel anti-cancer agents
toward human clinical trials."
Julie M. Cherrington is an
accomplished life science executive with a record of demonstrated
success bringing drug candidates into human clinical trials and
through to commercialization. She has been a key contributor to the
successful development of multiple FDA-approved products, including
the anti-cancer agents SUTENT® and PALLADIA®
and the ant-virals VISTIDE®, VIREAD®, and
HEPSERA®.
Dr. Cherrington has served as President and Chief Executive
Officer at several oncology companies, including Arch Oncology,
Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics. In
addition, she served as President and Executive Vice President,
R&D at Phenomix Corporation. Earlier in her career, Dr.
Cherrington was Vice President of Preclinical and Clinical Research
at SUGEN, a Pfizer company. Dr. Cherrington began her career at
Gilead Sciences, where she held a range of positions of increasing
responsibility. She has previously served on the Boards of
Directors of Chemgenex, Progen, Xenome, and Leading Biosciences.
Currently, she serves on the Boards of both QUE Oncology and Mirati
Therapeutics.
She serves on the Scientific Advisory Board of the Clearity
Foundation and is an advisor in several entrepreneurship
initiatives including the California Life Sciences Institute
(CLSI), UC San Francisco, Stanford, UC
Davis, and Equalize 2020 and 2021.
Dr. Cherrington holds a B.S. in biology and an M.S. in
microbiology from the University of
California, Davis. She earned a Ph.D. in microbiology and
immunology from the University of
Minnesota and Stanford
University. She completed a postdoctoral fellowship at the
University of California, San
Francisco.
In association with this appointment, the Company has granted
Dr. Cherrington incentive stock options to purchase up to an
aggregate of 125,000 common shares at $0.20 per share for a period of 5 years expiring
March 31, 2026.
About Rakovina Therapeutics Inc.
Rakovina Therapeutics
Inc. was established in 2020 to develop new cancer treatments based
on novel DNA-damage response technologies. The Company has
established a pipeline of DNA-damage response inhibitors with the
goal of advancing one or more drug candidates into human clinical
trials and obtaining marketing approval for new cancer therapeutics
from Health Canada, the United States Food and Drug Administration
and similar international regulatory agencies. Further
information may be found at www.rakovinatherapeutics.com.
Additional Information
The TSXV has in no way passed upon the merits of the
Qualifying Transaction and has neither approved nor disapproved the
content of this press release. Neither the TSXV nor its Regulation
Services Provider (as that term is defined in policies of the TSXV)
accepts responsibility for the adequacy or accuracy of this
release.
Notice regarding forward-looking statements:
This release includes forward-looking statements regarding
the Company and its respective business, which may include, but is
not limited to, statements with respect to the proposed business
plan of the Company and other statements. Often, but not always,
forward-looking statements can be identified by the use of words
such as "plans", "is expected", "expects", "scheduled", "intends",
"contemplates", "anticipates", "believes", "proposes" or variations
(including negative variations) of such words and phrases, or state
that certain actions, events or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved. Such statements
are based on the current expectations of the management of the
Company. The forward-looking events and circumstances discussed in
this release may not occur by certain specified dates or at all and
could differ materially as a result of known and unknown risk
factors and uncertainties affecting the Company, including risks
regarding the medical device industry, economic factors, regulatory
factors, the equity markets generally and risks associated with
growth and competition. Although the Company has
attempted to identify important factors that could cause actual
actions, events or results to differ materially from those
described in forward-looking statements, there may be other factors
that cause actions, events or results to differ from those
anticipated, estimated or intended. No forward-looking statement
can be guaranteed. Except as required by applicable securities
laws, forward-looking statements speak only as of the date on which
they are made and the Company undertakes no obligation to publicly
update or revise any forward-looking statement, whether as a result
of new information, future events, or otherwise. The
reader is referred to the Company's most recent filings on SEDAR
for a more complete discussion of all applicable risk factors and
their potential effects, copies of which may be accessed through
the Company's profile page at www.sedar.com.
SOURCE Rakovina Therapeutics Inc.